Enter a phase 2a proof of concept clinical study for ADX71149
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 21 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- June 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc, is scheduled to enter a phase 2a proof of concept clinical study for the treatment of epilepsy in Q2 2021.”
What we found
Evidence strength A What the grades mean
The company confirmed that its partner, Janssen, began the Phase 2a proof of concept clinical trial for ADX71149 in June 2021, meeting the Q2 2021 deadline.
-
A Addex Therapeutics Ltd. 20-F filed 2022-03-10
“Our partner, Janssen Pharmaceuticals, Inc., or Janssen, a subsidiary of Johnson & Johnson is conducting a placebo- controlled Phase 2a proof of concept clinical trial of ADX71149 in epilepsy patients since June 2021.” ✓ confirmed on the page
Market reaction: the shares moved -3.9% against the S&P 500 over the three sessions around the disclosure (9 Mar 2022 to 14 Mar 2022). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Enter
- Deliverable
- Phase 2a proof of concept clinical study for ADX71149
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Partner, Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Addex Therapeutics Ltd.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ADXN-022276 · Corrections policy